Search results
Results From The WOW.Com Content Network
[1] [2] ITP often results in an increased risk of bleeding from mucosal surfaces (such as the nose or gums) or the skin (causing purpura and bruises). [1] Depending on which age group is affected, ITP causes two distinct clinical syndromes: an acute form observed in children and a chronic
A woman with symptomatic thrombocytopenia and an identifiable anti-platelet antibody should be started on therapy for their ITP which may include steroids or IVIG. Fetal blood analysis to determine the platelet count is not generally performed as ITP-induced thrombocytopenia in the fetus is generally less severe than NAIT. Platelet transfusions ...
Symptoms of ITP include abnormal bleeding and bruising due to the reduction in platelet count. [20] Rh o (D) Immune Globulin Intravenous [Human; Anti-D] is indicated for use in non-splenectomized, Rh o (D)-positive children with chronic or acute ITP, adults with chronic ITP, and children and adults with ITP secondary to HIV infection. Anti-D ...
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Therapeutic plasma exchange (TPE) is a novel treatment for immune-mediated diseases and little research has been done for the effectiveness of TPE and patients with IMT. [15] TPE requires removing the patient's plasma which contains antibodies and replacing it with fluids such as sodium chloride , frozen plasma, packed red blood cells, and ...
Rigel reported results from two Phase III clinical trials for fostamatinib as an ITP treatment in August and October 2016. The study is the second Phase 3, multi-center, randomized, double-blind, placebo controlled, study of fostamatinib disodium in the treatment of persistent/chronic immune thrombocytopenic purpura that Rigel has conducted.
Thrombotic thrombocytopenic purpura (TTP) is a blood disorder that results in blood clots forming in small blood vessels throughout the body. [2] This results in a low platelet count , low red blood cells due to their breakdown , and often kidney , heart , and brain dysfunction. [ 1 ]
Eltrombopag was approved by the US Food and Drug Administration (FDA) in November 2008, for the treatment of thrombocytopenia in people with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulin therapy, or splenectomy.